- 专利标题: MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION
-
申请号: US13493827申请日: 2012-06-11
-
公开(公告)号: US20130096176A1公开(公告)日: 2013-04-18
- 发明人: Christopher John WRAIGHT , George Arthur Werther , Nicholas M. Dean , Kenneth W. Dobie
- 申请人: Christopher John WRAIGHT , George Arthur Werther , Nicholas M. Dean , Kenneth W. Dobie
- 申请人地址: AU Toorak
- 专利权人: Antisense Therapeutics Limited
- 当前专利权人: Antisense Therapeutics Limited
- 当前专利权人地址: AU Toorak
- 优先权: AUAU2003900609 20030211; AUAU2003902610 20030527
- 主分类号: C07H21/04
- IPC分类号: C07H21/04 ; C07H21/02 ; C07H21/00
摘要:
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition.
信息查询